Covid19, Critical Illness, Infection, Pediatric ALL, SARS-CoV Infection
Conditions
Keywords
Children, monitoring, immunodepression, HLA-DR, myeloid derived suppressor cell, neutrophil, phenotype
Brief summary
In this prospective longitudinal cohort the investigators reported the clinical, and biological characteristics of all critically ill patients admitted in the pediatric intensive care unit (PICU) of Bicêtre Hospital during the 2019 coronavirus disease (COVID-19) pandemics. Patients were older than 37 weeks of gestational age. No upper limit was set as the unit was transiently converted into a pediatric adult COVID-19 intensive care unit.
Detailed description
All patients will be monitored during their PICU stay. Clinical characteristics include: age, gender, co-morbidities, organ support therapies (mechanical ventilation, renal replacement therapy, extracorporeal membrane oxygenation, vasopressors), organ complications (pulmonary embolism, acute respiratory distress syndrome, renal failure, heart failure) and function, infective complications (ventilator associated pneumonia, central line associated bloodstream infection, pulmonary access, sepsis, septic shock), microbiologic and viral identification, 7-day and 28-day mortality. Biological characteristics include: * Admission workup: qualitative and quantitative Ig, ferritin, creatinine kinase, complement study (C3,C4,CH50), * Daily workup: blood cells count, arterial blood gas analysis, lactate, electrolytes, albumin, blood urea nitrogen, creatinine, hemostasis (fibrinogen, factor V, II+VII, factor X, prothrombin time, antiXa activity, activated cephalin time, D-dimer), C-reactive protein, procalcitonin. * Twice weekly workup: circulating cells phenotyping (T cell and subclass including Treg, B cell, Natural Killer cell, myeloid derived suppressor cell, neutrophils), interleukin 6. * Bone marrow analysis when indicated by attending staff.
Interventions
None listed
Sponsors
Bicetre Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients suspected or confirmed of severe acute respiratory syndrome Coronavirus 2 infection * No opposition from patients or legal representatives after study information * Patients admitted to the pediatric intensive care unit of Bicêtre Hospital, Assistance Publique Hôpitaux de Paris - Paris Saclay University * Between March 15, 2020 to June 31, 2021
Exclusion criteria
* Patient or legal representative refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patient with secondary infection | 2 weeks | Secondary infection will include healthcare associated infections as well as sepsis, and septic shock |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients dying | 7-day, 28-day and 60-day | mortality |
| Description of clinical phenotypes | through study completion, an average of 4 weeks | Description of the variable clinical phenotypes of COVID-19 in adults and children. This include COVID-19 respiratory failure, acute myocarditis and multi system inflammatory syndrome in children (MIS-C) |
| Description of immunological phenotypes | through study completion, an average of 4 weeks | Measure circulating cell phenotypes (relative percentage and monocyte classII histocompatibility complex |
Countries
France
Contacts
Primary ContactPierre Tissieres, MD, DSc
Backup ContactClemence Marais, MD, MSc
Outcome results
None listed